Author Correction: Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities

Affiliations

• ¹ Molecular Chemoprevention Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy.
• ² Oncogenomic and Epigenetic Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy.
• ³ Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
• ⁴ Unit of Endocrinological Gynecology, Ospedale Sant'Anna di Torino, Turin, Italy.
• ⁵ SAFU, 'Regina Elena' National Cancer Institute, Rome, Italy.
• ⁶ Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, ON, Canada.
• ⁷ Epigénétique et Épigénomique des Carcinomes Hépathocellulaires Viro-Induits du Centre de Recherche en Cancérologie de Lyon, Lyon, France.
• ⁸ Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
• ⁹ Division of Medical Oncology A, Italian National Cancer Institute 'Regina Elena', Rome, Italy.
• ¹⁰ Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada.
• ¹¹ Molecular Chemoprevention Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy. sabrina.strano@ifo.gov.it.
• ¹² Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada. sabrina.strano@ifo.gov.it.
• ¹³ Oncogenomic and Epigenetic Unit, Italian National Cancer Institute 'Regina Elena', Rome, Italy. giovanni.blandino@ifo.gov.it.
• ¹⁴ Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada. giovanni.blandino@ifo.gov.it.